Mr. Swapan Kakumanu reports

NETRAMARK ANNOUNCES CHANGE TO BOARD OF DIRECTORS

Netramark Holdings Inc.'s Lawrence Guy has resigned from the company's board of directors, effective May 7, 2026, for personal reasons.

The board and management of Netramark thank Mr. Guy for his service and contributions to the company, and wish him well in his future endeavours.

About Netramark Holdings Inc.

Netramark is a company focused on developing artificial intelligence and machine learning solutions for the pharmaceutical and clinical research industries. Its product offering is built on a proprietary, mathematically augmented learning system designed to analyze complex patient data sets and identify explainable subgroups of individuals that are related across multiple variables simultaneously. Through a differentiated mechanism for retaining and reinforcing meaningful signals across analytical pathways, Netramark's technology is designed to reveal clinically relevant structure in heterogeneous trial populations and support the development of actionable insights that may complement traditional AI/ML (artificial intelligence/machine learning) methods. Netramark's approach is intended to support the analysis of smaller and complex clinical data sets, including applications related to disease segmentation, patient stratification, drug sensitivity analysis and the identification of treatment efficacy signals in clinical trial data.

For further details on the company, please see the company's publicly available documents filed on SEDAR+.

We seek Safe Harbor.